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The potential for human exposure to the diverse and ever-
changing world of nanoscale materials has raised concerns about
their influence on health and disease. The novel physical and chem-
ical properties of these materials, which are associated with their
small size, complicate toxicological evaluations. Further, these
properties may make engineered nanomaterials (ENMs) a prime
target for interaction with the immune system following uptake
by phagocytes. Undesired effects on antigen-presenting cells and
other phagocytic cells are of concern due to the high likelihood
of ENM uptake by these cells. In addition, ENM interactions with
lymphocytes and other cell types can contribute to a varied spec-
trum of possible effects, including inflammation, hypersensitivity,
and immunomodulation. Furthermore, the mast cell (a type of im-
mune cell traditionally associated with allergy) appears to con-
tribute to certain inflammatory and toxic effects associated with
some ENMs. Although incidental exposure may be undesirable,
nanomedicines engineered for various clinical applications provide
opportunities to develop therapies that may or may not intention-
ally target the immune system. The interaction between ENMs and
the immune system and the resulting pharmacokinetic and pheno-
typic responses are critical factors that dictate the balance between
toxicity and clinical efficacy of nanotherapeutics.
Key words: nanomaterials; immune system; immunotoxicity;
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Don’t eat that. . . it contains “toxic” nanoparticles! What are
nanomaterials anyway? And why should we care about them?
They’re so small. . . how can they be toxic? What do you mean
are they “different” than larger particles? Wait. . . can they ac-
tually be beneficial? What’s the immune system have to do
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with any of this, anyway? Sound familiar? These statements
and questions, and many others like them, are increasingly be-
ing asked in the midst of today’s global engineered nanomaterial
(ENM) “frenzy.” The fact is, in recent years, there has been con-
siderable research examining the potential utility of nanoscale
materials and nanostructures in commercial and biomedical ap-
plications. So what do we make of this attention, and how can
the scientific community effectively answer such questions and
concerns? This forum article covers a symposium of the same
title presented at the 52nd Annual Meeting of the Society of
Toxicology, held in March 2013, in San Antonio, Texas, which
sought to bring attention to issues surrounding ENM toxicity
evaluations, ENM-immune system interactions, and important
considerations related to the use of ENMs in medicine.
SMALL MATERIALS, LARGER ISSUES
Broadly defined, ENMs are a set of substances with at least
one critical dimension less than 100 nm. Because of their small
size, ENMs are believed to possess novel chemical and phys-
ical properties that make them useful in various applications.
However, these same properties can also make their interactions
with biological systems difficult to predict and evaluate in tra-
ditional toxicity models (Balbus et al., 2007; Hoet et al., 2009).
Further complicating matters is the fact that ENMs are not a sin-
gle “class” of agents that can be treated as a single entity, due
to considerable diversity in size, composition, surface modifi-
cations, and physicochemical properties. Even within a given
“class” there is variability among what otherwise may appear
to be “similar” ENMs. For example, nanotubes differ by tube
status (single, double, and multi-walled), tube length and diam-
eter, surface modifications, and metal composition (as a syn-
thetic byproduct during synthesis; Donaldson et al., 2006). This
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diversity makes the translation of toxicological findings from
one ENM to another problematic.
Another issue related to assessing the safety of ENMs is the
relevance of the “tested agent.” Currently, there is limited infor-
mation on specific agents with known human exposure, as well
as the characteristics of ENMs to which people are exposed.
Consequently, the choice of a specific agent to evaluate may be
based on pragmatic decisions such as commercial availability,
instead of known human exposure. Further, the physicochemi-
cal properties of an ENM may change within the test system. For
example, it is known that proteins adsorb to the surface of ENMs
in the body (Cedarvall et al., 2007; Monopoli et al., 2012), form-
ing a protein corona that fundamentally changes the physical
and chemical characteristics of the ENM that had been so care-
fully characterized. How do these coronas influence extrapola-
tion from in vitro to in vivo studies, and are the differences of
any toxicological consequence, or are they simply phenomeno-
logical?
Defining how best to characterize the “dose” further compli-
cates ENM toxicological assessments. Indeed, comparing the
toxicity and potency of materials based on simple mass-based
dose metrics (e.g., mg/kg) may not be appropriate (Oberdorster
et al., 2007). For example, in some metal oxides, where the bi-
ological effects of materials are driven by properties related to
the surface area of a material, it is more appropriate to compare
different-sized materials basing the dose administered on the to-
tal surface area, rather than on mass. The issue of dose extrapo-
lation between in vivo and in vitro exposure is also of concern.
At present, there is little correlation between in vitro and in vivo
toxicity profiles for nanoparticles (Sayes et al., 2007). As noted
by Teeguarden et al. (2007), differences in diffusion and settling
of nanoparticles—or “particokinetics”—in solution during in
vitro studies can lead to differences in ranking of ENMs despite
similar mass doses. Mathematical models of particle behavior
and dosimetry in vitro are also being considered in order to re-
late dosage to cells with specific adverse outcomes (Hinderliter
et al., 2010). Further, the absorption, distribution, metabolism,
and elimination kinetics of ENMs can be affected by particle
size and surface coating/chemistry. For example, a clear size
dependency was reported in the translocation of polystyrene
microspheres (50, 100, 300, 500, 1000, and 3000 nm) across
the gastrointestinal tract following oral administration to female
Sprague Dawley rats, with increased translocation associated
with decreased particle sizes (Jani et al., 1990).
ENMS AND THE IMMUNE SYSTEM
Phagocytic cells of the immune system, including
macrophages, neutrophils, and dendritic cells, are respon-
sible in part for ENM uptake (Patri et al., 2007). ENM
interactions with cells of the immune system, including
phagocytes, lymphocytes, and mast cells, can be altered by
ENM physicochemical properties, including size and surface
modification (Fischer and Chan, 2007). For example, there are
reports of both increased and abrogated uptake of single-walled
carbon nanotubes, depending upon the surface functional group
(Antonelli et al., 2010; Singh et al., 2006), suggesting a role for
surface modifications in mediating immune recognition and/or
uptake of ENMs. Further, ENM size has been correlated with
activation of the complement system (Pedersen et al., 2010).
Current predictive and validated immunotoxicity testing
strategies, Tkach et al. (2011) using a tiered approach, have
been well established (Luster et al., 1988) but have been
used infrequently to evaluate ENMs. Some well-established as-
says include the mononuclear phagocytic system (MPS) assay
(Munson et al., 1970) for innate immunity, the plaque assay
(Jerne et al., 1963), the enzyme-linked immunosorbent assay for
T-dependent antibody responses (humoral immunity), and the
delayed-type hypersensitivity assay (Smith and White, 2010;
White et al., 2012) for cell-mediated immunity (CMI). Contact
hypersensitivity responses are regularly assessed using the lo-
cal lymph node assay (LLNA); however, many ENMs cannot
penetrate the stratum corneum of intact skin. In such cases, the
lymph node proliferation assay (LNPA; Weaver et al., 2005),
which utilizes subcutaneous (s.c.) administration, may be a use-
ful alternative (Dobrovolskaia et al., 2009), although it has not
been validated for assessing ENM hypersensitivity. In fact, it is
currently unclear whether any of the “traditional” immunotoxi-
cology methods are sensitive and predictive of ENM-mediated
immunotoxicity, as well as how they can/should be modified to
better predict ENM immunomodulation.
ENM MODULATION OF IMMUNE FUNCTION
Consider a handful of studies that have evaluated immune ef-
fects of titanium dioxide nanoparticles. A recent series of studies
evaluated the immunotoxicity of anatase nano-TiO2 using var-
ious routes of exposure (dermal, s.c., and oral gavage) at doses
up to 250 mg/kg (Auttachoat et al., 2013). Dermal exposure
for three days produced irritancy but not contact hypersensitiv-
ity (LLNA), although the LNPA demonstrated significant in-
creases consistent with either inflammation/irritation or a pos-
sible hypersensitivity response. The authors also reported that
oral exposure for 28 days produced no immune effects (innate,
humoral, and CMI). Contrasting with the negative findings for
the oral immunotoxicity studies by Auttachoat et al. (2013), an-
other recent study evaluating oral exposure to TiO2 nanopar-
ticles reported increased mast cell activation within the stom-
achs of young rats (Wang et al., 2013b). Whereas the Autta-
choat et al. studies did not specifically evaluate mast cells, these
findings further the concern as to whether or not the current
immunotoxicity testing strategies are sufficiently sensitive and
predictive or even appropriate for ENM immunotoxicity eval-
uations. Clearly, immunotoxicity testing of ENMs is anything
but straightforward. Table 1 provides some examples of the va-
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TABLE 1


















Increase in numbers of neutrophils in lung Gustafsson et al.
(2011)
Neutrophils Intragastric Decrease in numbers of neutrophils in the blood Sang et al. (2012)
Dendritic cells In vitro Upregulated expression of MHC-II, CD80, and CD86 Winter et al. (2011)
T cells Intragastric Decreased the proliferation of both CD4+ and CD8+ T
cells, as well as the ratio of CD4+ to CD8+ cells in the
liver
Duan et al. (2010)
B and NK cells Intraperitoneal Delayed B-lymphocyte development; decrease in
numbers of spleen resident NK cells, specifically
CD11b− NK cells
Moon et al. (2011)
B cells Intratracheal
installation
Increase in numbers of B cells in the spleen and whole
blood as well as increased production of IgE in lung
lavage fluid
Park et al. (2009)
NK cells Intratracheal
installation
Increase in numbers of NK cells in lung as well as a




NK cells Intragastric Decrease in whole blood NK cell numbers Sang et al. (2012)
Mast cells In vitro Activating mast cells to release histamine through
membrane L-type Ca2+ channels
Chen et al. (2012)
Mast cells Oral gavage Reported increased mast cell activation in stomachs of
young rats
Wang et al. (2013b)
Carbon
nanotubes
T and NK cells Inhalation Immunosuppression of T-cell-dependent antibody
responses and NK cell activity
Mitchell et al. (2007)
Macrophages In vitro MWCNTs induce COX-2 production through a
MAPK-dependent mechanism and iNOS production
through a MAPK-independent mechanism
Lee et al. (2012)
Macrophages In vitro Increases in cytokine release including IL-1, IL-6,
and IL-8 from human macrophage cell line
Murphy et al. (2012)
Dendritic cells Oropharyngeal
aspiration
Increased lung inflammation, but systemic
immunosuppression of dendritic cells leading to
decreased T-cell proliferation
Tkach et al. (2011)
T cells Intravenous Increases in both CD4+ and CD8+ T cells in the spleen
of C57BL/6 mice dependent on nanomaterial
(comparison of graphene and carbon nanotubes)
Wang et al. (2013a)
Mast cells Oropharyngeal
aspiration
IL-33, released from damaged lung epithelial cells by
MWCNT exposure, subsequently activated mast cells
resulting in adverse cardiopulmonary responses
Wang et al. (2011)
Katwa et al. (2012)
Splenocytes Oropharyngeal
aspiration
Single-walled carbon nanotubes (SWCNTs) do not
impact the early immune response to Toxoplasma
gondii in mice.
Swedin et al. (2012)
Fullerenes Basophils In vitro Inhibit IgE dependent activation of peripheral basophil
activation
Ryan et al. (2007)
Norton et al. (2010)
Mast cells Intraperitoneal A significant reduction in the mast-cell-dependent
anaphylactic-induced drop in core body temperature
as well as behavioral responses that accompany
anaphylactic shock
Norton et al. (2010)
riety of NM-immune interactions that have been reported for
TiO2 nanoparticles, carbon nanotubes, and carbon fullerenes.
In addition to concern that ENM exposure can modulate nor-
mal immune function, ENM-immune cell interactions may re-
sult in unforeseen activation of one or more immune cell types.
The implications of activating immune cells may be significant
and may have toxicological impact on other critical systems.
In fact, there is increasing evidence that one immune cell in
particular—the mast cell—may play a role in the initiation of
both pulmonary and cardiovascular events following ENM ex-
posure (Shannahan et al., 2012). Mast cells have long been rec-
ognized for their role in the genesis of allergic inflammation
in diseases such as asthma, atopic dermatitis, allergic rhinitis,
allergic eye disease, and anaphylaxis (Brown et al., 2008). In-
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deed, the activation of mast cells by ENM may pose a significant
hurdle to the development of safe nanotechnologies to avoid de-
velopment of these allergic conditions, but also to prevent any
unwanted anaphylactic-type responses that could be associated
with nanotherapeutics.
Increasing evidence suggests that mast cells may be recruited
by ENM exposure and can contribute significantly to ENM
toxicity. For example, a study by Murray et al. (2009) found
that dermal exposure to single-walled carbon nanotubes resulted
in increased epidermal thickening and activation of dermal fi-
broblasts, which the authors suggested was due to accumu-
lation of neutrophils and mast cells in the skin. A more re-
cent study using multi-walled carbon nanotubes (MWCNTs),
which have well documented pulmonary and cardiovascular
toxicity (Wang et al., 2011), has begun to elucidate mecha-
nisms by which mast cells may contribute to ENM toxicity
(Katwa et al., 2012). In this study, oropharyngeal aspiration
of MWCNTs elicited a robust release of IL-33 into the bron-
choalveolar lavage fluid and suggested damage to the epithe-
lium (Katwa et al., 2012). IL-33, which signals through the ST2
(IL-1RL1) receptor (Ali et al., 2007; Ho et al., 2007; Iikura et
al., 2007) has recently been described as a significant mecha-
nism of mast cell activation, leading to production of several
pro-inflammatory cytokines under acute exposure conditions
(Ho et al., 2007; Iikura et al., 2007). The pathologies associated
with MWCNT inhalation—including inflammation, pulmonary
fibrosis, airway functional changes, and adverse cardiovascular
events (Wang et al., 2011)—appeared to be mast cell depen-
dent in this model, as MWCNT failed to induce these toxici-
ties in KitW-sh mice (Katwa et al., 2012). Overall, these find-
ings demonstrated a lack of adverse toxicological responses to
MWCNT when there was a deficiency of mast cells or when
the mast cells were unable to respond to IL-33. In contrast to
MWCNTs, work by Ryan et al. (2007) has demonstrated that
another carbon-based ENM, fullerene C60, inhibits mast-cell-
mediated allergic responses, suggesting that the aspect ratio of
MWCNTs likely contributes to immune activation and further
illustrating the connection between physicochemical properties
of ENMs and the resulting responses of the immune system.
The role of mast cells in mediating ENM toxicity is concern-
ing, particularly in light of the inability to evaluate these cells us-
ing the current validated immunotoxicity testing battery. Many
questions remain, including “if” and “how” ENMs promote al-
lergic responses through development of antigen-specific IgE,
activation of basophils, and exacerbation of underlying allergic
conditions. Indeed, more effort needs to be focused within the
general area of allergic responses to ENMs, as this may repre-
sent a likely immune outcome following exposure.
NANOTHERAPEUTICS AND THE IMMUNE SYSTEM
Carrier-mediated agents consist of nanoparticles, nanosomes
(nanoparticle-sized liposomes), and conjugates. Theoretical ad-
vantages of carrier-mediated drugs include increased drug sol-
ubility, prolonged duration of exposure, selective delivery of
entrapped drug to the site of action, and improved therapeutic
index. The disposition of encapsulated drug is dictated by the
composition of the carrier, thus altering the pharmacokinetic
(PK) profile of the drug. The phagocytes of the MPS are one
proposed clearance pathway of nanotherapeutic agents. Studies
suggest there is a bidirectional interaction between nanosomal
agents and the MPS. However, potential factors associated with
the clearance and disposition of carrier agents in patients and
preclinical animal models have not been extensively evaluated.
A phase I study has been reported in which the relation-
ships between the disposition of the carrier-mediated agent S-
CKD602 (PEGylated liposomal CKD-602, a camptothecin ana-
logue) and changes in monocytes and absolute neutrophil counts
were evaluated (Zamboni et al., 2010). Results of this evaluation
of the PK and pharmacodynamic (PD) relationships between a
liposomal anticancer agent and immune cells in patients sug-
gested that monocytes were more sensitive to S-CKD602 than
neutrophils. The increased sensitivity appeared to be related to
the liposomal formulation and not the released drug from the
liposome or the small molecule formulation. Thus, there is pre-
liminary evidence suggesting that factors associated with the
MPS may contribute to PK and PD variability of nanotherapeu-
tics. As such, there is a compelling need to identify the rele-
vant factors associated with MPS function in order to improve
the preclinical and clinical studies of ENMs. Further, it will be
essential to test whether the PK of ENM can be scaled across
species using various measurements and surrogates of the MPS,
such as monocyte and macrophage activity or function, genet-
ics, complement, or cytokines.
Finally, it is important to emphasize that timely considera-
tion must be given to the effects of nanotherapies on the many
components of the immune system well in advance of the clin-
ical trial stage. Indeed, in initial design stages, the carrier ENM
should carefully be selected to avoid undesired immune effects.
Here, a key point emerges. If suppression or stimulation of an
immune response is the desired result, then a certain degree of
immunotoxicity of the carrier ENM and/or the delivered drug
may be appropriate. For example, if an ENM carrier were used
to deliver vaccines, then stimulation of the immune system by
the ENM carrier would be desired. Some ENMs have been
shown to possess potent adjuvant effects, capable of augment-
ing immune responses directed against antigens (de Haar et al.,
2006; Dobrovolskaia and McNeil, 2007; Zolnik et al., 2010).
Indeed, the number of publications detailing investigations of
ENM vaccines has increased exponentially since 2007.
Recently, it has been shown that physicochemical properties
play an important role in the adjuvant-like responses elicited
by ENMs (Sun et al., 2013). In the study by Sun et al. (2013),
the use of aluminum oxyhydroxide nanomaterials with varying
shape (rods, plates, or polyhedrons) and crystallinity resulted in
improved adjuvant capacity compared with alum in both in vitro
(dendritic cell activation) and in vivo (IgG and IgE responses
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to ovalbumin) studies. In addition to adjuvant responses, it has
recently been demonstrated that nanoparticle shape influences
antibody and cytokine production (Niikura et al., 2013). In this
study, the shape and size of gold nanoparticles (AuNP) coated
with West Nile virus envelope protein influenced the production
of specific antibodies in mice, with a spherical AuNP resulting
in the highest level of antibody production whereas a rod-shape
AuNP produced half the level of antibody (Niikura et al., 2013).
Further, the cytokine profile produced by macrophages and den-
dritic cells varied depending on the shape, with the rod-shaped
AuNP resulting in inflammasome activation and subsequent IL-
1 and IL-18 release, whereas the spherical AuNPs induced
TNF-, IL-6, IL-12, and GM-CSF (Niikura et al., 2013).
Whereas most traditional immunotoxicological studies have
focused on immunosuppression, most nanoparticle studies have
examined their inflammatory properties. However, other stud-
ies have shown that nanoparticles can be used to deliver im-
munosuppressive drugs. Cyclosporine A-conjugated polymeric
nanoparticles have been shown to suppress T-cell function
through downregulation of priming by dendritic cells (Azzi
et al., 2010). In addition, local delivery of an immunosuppres-
sive drug may be advocated, if local suppression of an undesired
immune response is required. The feasibility of such therapy
was demonstrated by McLoughlin et al. (2011) and McLoughlin
(2012) in studies where an immunosuppressive drug was incor-
porated into nanofibrous biomaterials. Following s.c. implanta-
tion in mice, this biomaterial exhibited sustained drug release,
and a therapeutic window was identified, in which local im-
munosuppression was achieved without systemic immunotoxic
effects. Ultimately, the interpretation of effects that nanothera-
pies may exert on the immune system is dependent on the in-
tended application.
FUTURE RESEARCH DIRECTIONS
Many key questions remain unanswered. If ENM exposure
has the potential to modulate immune function, and modula-
tion of the function of certain immune cells (e.g., mast cells,
lymphocytes, and phagocytic cells) in turn may contribute to
other toxicities, how can ENM toxicity be evaluated, and can
this snowball effect be avoided? Furthermore, given the inter-
action of ENMs with the cells of the immune system, is it pos-
sible to find or engineer ENMs, having certain desired physical
and chemical characteristics, that can be used to engage and di-
rect the immune system, without undesirable adverse toxicity,
for therapeutic/medicinal purposes? If so, can these nanother-
apeutics be controlled or directed? What cell(s) should they be
designed to target? Are the PK and PD profiles of nanotherapeu-
tics similar to those of more conventional medicinal therapies?
And how can this be evaluated in order to establish appropriate
first-in-man doses? These questions and many others must be
considered in future research as nanotherapeutics are increas-
ingly explored.
CONCLUDING SUMMARY
Interactions between ENMs and the immune system are un-
avoidable, and concerns about the possibility of ENM-mediated
immunomodulation promote a growing need to evaluate the ef-
fects of these novel materials on the many facets of the immune
system. Conversely, ENM toxicity that is mediated by one or
more types of immune cells adds a further complication. How-
ever, by investigating the bidirectional ENM-immune cell in-
teractions, the resulting toxic effects, and the mechanisms by
which these effects occur, we can better characterize the hazards
these materials pose in order to select—with knowledge and
forethought—appropriate nanotherapeutics for use in medicinal
applications.
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